EGFR and non-small cell lung carcinoma: In addition, another randomized phase II study was performed to evaluate the feasibility of combination treatment with pembrolizumab plus docetaxel in patients with pre-treated advanced NSCLC following chemotherapy regardless of EGFR mutations8.